Shares of Vertex (VRTX +2.87%) skyrocketed today, on very exciting news coming from a phase 2 trial of one of the company's cystic fibrosis drugs. Is Vertex the next big biotech that investors need to be a part of? In this video, Motley Fool health-care analyst David Williamson talks about the phase 2 results, and why investors should stand up and pay attention, and tells us where the company could go in 2013.
Is This Stock the Next Big Biotech?
By Dave Williamson – Apr 19, 2013 at 7:01PM
NASDAQ: VRTX
Vertex Pharmaceuticals
Market Cap
$104B
Today's Change
(2.87%) $11.73
Current Price
$421.20
Price as of November 10, 2025 at 4:00 PM ET
Shares of Vertex exploded today. Is this one you need to be in on?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid